SG Americas Securities LLC Grows Stock Position in Insulet Corporation $PODD

SG Americas Securities LLC raised its position in Insulet Corporation (NASDAQ:PODD) by 712.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 318,848 shares of the medical instruments supplier’s stock after acquiring an additional 279,587 shares during the quarter. SG Americas Securities LLC’s holdings in Insulet were worth $66,907,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Evolve Private Wealth LLC boosted its stake in shares of Insulet by 160.6% in the first quarter. Evolve Private Wealth LLC now owns 2,450 shares of the medical instruments supplier’s stock valued at $514,000 after purchasing an additional 1,510 shares during the period. Rockefeller Capital Management L.P. lifted its holdings in Insulet by 488.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 3,343 shares of the medical instruments supplier’s stock worth $950,000 after buying an additional 2,775 shares in the last quarter. Corient Private Wealth LLC boosted its position in Insulet by 35.0% in the 4th quarter. Corient Private Wealth LLC now owns 14,595 shares of the medical instruments supplier’s stock valued at $4,160,000 after buying an additional 3,782 shares during the last quarter. Sit Investment Associates Inc. boosted its position in Insulet by 13.9% in the 4th quarter. Sit Investment Associates Inc. now owns 18,634 shares of the medical instruments supplier’s stock valued at $5,297,000 after buying an additional 2,277 shares during the last quarter. Finally, MidFirst Bank acquired a new stake in shares of Insulet during the fourth quarter valued at about $394,000.

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.36% of the stock is owned by insiders.

Insulet Price Performance

PODD opened at $138.97 on Tuesday. The company has a market capitalization of $9.63 billion, a P/E ratio of 32.32, a PEG ratio of 1.15 and a beta of 1.13. The company has a 50-day moving average of $162.97 and a 200-day moving average of $224.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 1-year low of $138.79 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts expect that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the topic of a number of analyst reports. Piper Sandler dropped their target price on Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. UBS Group set a $219.00 price objective on Insulet in a research note on Thursday, June 11th. Canaccord Genuity Group dropped their price objective on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Wells Fargo & Company cut their target price on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, Truist Financial cut their target price on Insulet from $250.00 to $219.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $240.78.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.